Adaptimmune selects cell therapy third-party PCT to make SPEAR T-Cells
Adaptimmune Therapeutics has entered a five-year manufacturing deal with PCT for its SPEAR T-cell pipeline ahead of the opening of its own facility in Philadelphia.
Adaptimmune Therapeutics has entered a five-year manufacturing deal with PCT for its SPEAR T-cell pipeline ahead of the opening of its own facility in Philadelphia.
GE Healthcare is in discussions with companies looking to buy four fully-equipped ‘off-the-shelf’ facilities as part of a €150m investment into a biomanufacturing campus in Ireland.
Horizon Discovery says flexibility and openness helped the UK’s Centre for Process Innovation (CPI) and Ireland’s NIBRT choose to provide its GS null CHO cell line to the biologics industry.